Integra LifeSciences Holdings Corporation announced the appointment of Teshtar Elavia as corporate vice president and chief technology officer, a newly created position to lead research and development (R&D), including product and technology development, across the company. The company also announced the appointments of Michael Hutchinson as executive vice president, chief legal officer and secretary, and Kerri DiPietro as corporate vice president and chief quality officer. The creation of the chief technology officer (CTO) position underscores Integra?s commitment to building a more connected innovation engine to advance long-term growth.
As CTO, Teshtar Elavia will work to align R&D priorities with the company?s strategic imperatives, accelerate the impact and speed of product development programs, and strengthen the company?s innovation pipeline through organic and partnership efforts. He will also help identify emerging trends and technologies that reinforce the company?s market leadership and provide opportunities for future growth. Elavia brings more than 20 years of experience in new product development spanning imaging and navigation, minimally invasive surgery, regenerative medicine, diabetes care, and autoimmune diseases, with senior R&D leadership roles at Becton Dickinson, Eli Lilly, Medtronic, and Johnson & Johnson.
Most recently, he served as vice president of R&D for Becton Dickinson?s Medical Delivery Solutions business, where he led the development of an R&D roadmap to drive growth in high-value markets and advanced connected care innovation initiatives. Michael Hutchinson will lead the company?s global legal, compliance, and environmental, social and governance (ESG) functions and serve as the principal legal advisor to the executive leadership team and board of directors. He is a seasoned attorney and business leader with more than 20 years of experience spanning complex litigation, corporate governance, risk management, ESG matters, and more than 80 acquisitions and integrations.
Prior to joining Integra, Hutchinson served as senior vice president and chief legal officer at LivaNova, with prior chief legal officer roles at Stryker and Varian Medical Systems. Kerri DiPietro will lead Integra?s global quality organization, driving the execution of the company?s enterprise-wide Compliance Master Plan and overseeing the strengthening and harmonization of the global quality management system. Her responsibilities will encompass all global quality activities, including design assurance, post-market surveillance, supplier quality, complaint handling, and validation. DiPietro joins Integra from Haemonetics, where she served as senior vice president of global quality and compliance, and led transformational improvements in product quality, regulatory compliance, and global quality system integration.
Prior to Haemonetics, she was at Boston Scientific, where she held roles of increasing responsibility in R&D, operations and quality.
